{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135260","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.550468+00:00","generated_at":"2026-06-02T06:57:10.805546+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Invivyd Q1 net loss $43.5M ($0.38/sh); launches PEMGARDA, guides 2024 rev $150-200M","bullets":["Launched PEMGARDA (pemivibart) for COVID-19 PrEP in immunocompromised; received CMS HCPCS Q and M codes.","Cash $189.4M at Q1 end; expects ≥$75M year-end cash on $150-200M net product revenue.","Net loss $43.5M vs $35.3M YoY; R&D $31.2M, SG&A $14.9M.","Plans to submit EUA for pemivibart as COVID-19 treatment in immunocompromised via rapid immunobridging.","Advancing VYD2311 mAb candidate optimized against BA.2.86/JN.1 lineages."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135260","json":"https://secwatch.observer/filing/0001193125-24-135260.json","markdown":"https://secwatch.observer/filing/0001193125-24-135260.md","text":"https://secwatch.observer/filing/0001193125-24-135260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524135260/0001193125-24-135260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524135260/d838072d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:57:10.805546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76138ca1de63c7ea8390cb6a5239d13a66abb8a9","claim":"Invivyd, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $43.5 million for the quarter ended March 31, 2024, compared to $35.3 million for the comparable period in, EPS Basic and diluted net loss per share was $0.38 for the quarter ended March 31, 2024, compared to $0.32 for the comparabl. Guidance reaffirmed.","evidence_excerpt":"On May 9, 2024, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024, and recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312524135260/0001193125-24-135260-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $43.5 million for the quarter ended March 31, 2024, compared to $35.3 million for the comparable period in"},{"label":"EPS","value":"Basic and diluted net loss per share was $0.38 for the quarter ended March 31, 2024, compared to $0.32 for the comparabl"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}